Cadmus Rich - Oct 31, 2022 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Role
Chief Medical Officer, Head of R&D
Signature
/s/ Julie Feder, as Attorney-in-Fact
Stock symbol
AURA
Transactions as of
Oct 31, 2022
Transactions value $
-$20,813
Form type
4
Date filed
11/2/2022, 08:38 PM
Previous filing
Oct 28, 2021
Next filing
Jan 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AURA Common Stock Sale -$20.8K -1.67K -6.37% $12.45 24.6K Oct 31, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.40 to $12.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

Chief Medical Officer, Head of R&D